Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.43 |
| ▸ | GBA1 | P04062 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.37 |
| ▸ | CD274 | Q9NZQ7 | 3/20 | 0.37 |
| ▸ | PDCD1LG2 | Q9BQ51 | 2/20 | 0.37 |
| ▸ | FAAH | O00519 | 1/20 | 0.36 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.36 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4291807 | 0.81 | KMT2A (0.48) | ACHEKDM4EALDH1A1LMNAMAPT | |
| SCHEMBL3398877 | 0.80 | VEGFA (0.46) | ALDH1A1TDP1MAPTSMN1; SMN2HTT | |
| SCHEMBL13861951 | 0.78 | ACHE (0.65) | ACHEKDM4EALDH1A1LMNATDP1 | |
| SCHEMBL15065984 | 0.77 | ACHE (0.63) | ACHEKDM4EALDH1A1TDP1MAPT | |
| SCHEMBL3110747 | 0.76 | KDM4E (0.63) | KDM4EALDH1A1MAPTHTTFAAH | |
| SCHEMBL3396517 | 0.75 | GBA1 (0.61) | ALDH1A1LMNAGBA1S1PR1S1PR5 | |
| SCHEMBL4297559 | 0.74 | LMNA (0.60) | ACHEKDM4EALDH1A1LMNATDP1 | |
| SCHEMBL15687883 | 0.74 | ALDH1A1 (0.54) | ACHEKDM4EALDH1A1LMNATDP1 | |
| SCHEMBL520610 | 0.74 | CYP2A13 (0.61) | ACHEKDM4EALDH1A1TDP1MAPT | |
| SCHEMBL4371470 | 0.73 | LTA4H (0.41) | ACHEKDM4EALDH1A1LMNATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8420657-B2 | Pyrrolo[2,3-D]pyrimidines and use thereof as tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2013-04-16 | — | — | US | disclosed |
| US-20090203688-A1 | HETEROCYCLIC COMPOUNDS | NOVARTIS AG | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203688-A1 | HETEROCYCLIC COMPOUNDS | ABL1, JAK2, JAK1 | ACHE 4251/4885KDM4E 1741/4885ALDH1A1 1389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.